研究者データベース


フリーワードで探す

全文検索となっています

金光 禎寛カネミツ ヨシヒロ

所属部署医学研究科呼吸器・免疫アレルギー内科学分野
職名助教
メールアドレス
ホームページURL
生年月日
Last Updated :2020/06/02

研究者基本情報

基本情報

    科研費研究者番号:20765268
    ORCID ID:0000-0002-1529-9477

学歴

  • 2011年04月 - 2015年03月, 京都大学大学院医学部医学研究科
  • 1998年04月 - 2004年03月, 川崎医科大学

経歴

  •   2015年04月 - 現在, 名古屋市立大学大学院医学研究科, 呼吸器・免疫アレルギー内科学, 助教

研究活動情報

研究分野

  • ライフサイエンス, 呼吸器内科学

研究キーワード

    慢性咳嗽, 喘息

論文

  • High serum free IL-18 level is associated with allergic but non-eosinophilic inflammation; findings from a study of 2-year omalizumab treatment., Chie Morimoto, Hisako Matsumoto, Tomoko Tajiri, Yasuhiro Gon, Reiko Ito, Shu Hashimoto, Maho Suzukawa, Ken Ohta, Kenji Izuhara, Junya Ono, Shoichiro Ohta, Isao Ito, Tsuyoshi Oguma, Yoshihiro Kanemitsu, Tadao Nagasaki, Yumi Izuhara, Akio Niimi, Toyohiro Hirai, The Journal of asthma : official journal of the Association for the Care of Asthma, 1 - 17,   2020年05月07日, 査読有り, Objective: Omalizumab is more effective in severe allergic patients with eosinophilic asthma than those with non-eosinophilic asthma. IL-18, a unique cytokine involved in allergic but non-eosinophilic inflammation, might be associated with the latter condition. We aimed to clarify the roles of IL-18 related pathways in insufficient response to omalizumab treatment.Methods: Patients with severe allergic asthma who completed 2-year omalizumab treatments at Kyoto University Hospital were included in this study (UMIN000002389). Associations between pre-treatment levels of serum free IL-18 in addition to other mediators and asthma phenotypes including responses to omalizumab treatment were analyzed. Changes in serum free IL-18, periostin and total IgE levels during the treatment were also examined.Results: Twenty-seven patients (19 females, average age of 55.7 years) were examined. Fifteen incomplete responders who experienced exacerbations in the second year, were significantly and more frequently obese and showed significantly earlier asthma onset, lower blood eosinophils and more exacerbations before omalizumab treatment than complete responders. Significantly more patients showed high baseline serum free IL-18 levels (≥141 pg/mL, a threshold for the highest tertile) among the incomplete responders than complete responders. Patients with high serum free IL-18 levels shared similar characteristics with incomplete responders, showing significant reductions in serum total IgE levels during omalizumab treatment. Finally, serum free IL-18 levels negatively correlated with serum periostin levels at baseline and in change ratios.Conclusions: High baseline serum free IL-18 levels may predict reduced omalizumab efficacy in severe allergic patients with type-2 low asthma, regarding reduction of exacerbations.
  • Interfering with airway nerves in cough associated with asthma., Niimi A, Fukumitsu K, Takeda N, Kanemitsu Y, Pulmonary pharmacology & therapeutics, 59,   2019年12月, 査読有り
  • Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough., Kanemitsu Y, Kurokawa R, Takeda N, Takemura M, Fukumitsu K, Asano T, Yap J, Suzuki M, Fukuda S, Ohkubo H, Maeno K, Ito Y, Oguri T, Niimi A, Allergology international : official journal of the Japanese Society of Allergology, 68, (4) 478 - 485,   2019年10月, 査読有り
  • Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation., Takeda N, Takemura M, Kanemitsu Y, Hijikata H, Fukumitsu K, Asano T, Yamaba Y, Suzuki M, Kubota E, Kamiya T, Ueda T, Niimi A, The Journal of asthma : official journal of the Association for the Care of Asthma, 1 - 9,   2019年07月, 査読有り
  • Small airway inflammation is associated with residual airway hyperresponsiveness in Th2-high asthma., Asano T, Kanemitsu Y, Takemura M, Fukumitsu K, Kurokawa R, Inoue Y, Takeda N, Yap JMG, Ito K, Kitamura Y, Fukuda S, Ohkubo H, Maeno K, Ito Y, Oguri T, Niimi A, The Journal of asthma : official journal of the Association for the Care of Asthma, 1 - 9,   2019年06月, 査読有り
  • Aortoesophageal Fistula Occurring During Lung Cancer Treatment: A Case Treated by Thoracic Endovascular Aortic Repair., Ito K, Oguri T, Nakano A, Fukumitsu K, Fukuda S, Kanemitsu Y, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A, Internal medicine (Tokyo, Japan),   2019年06月, 査読有り
  • Induction of airway remodeling and persistent cough by repeated citric acid exposure in a guinea pig cough model., Cui S, Ito I, Nakaji H, Iwata T, Matsumoto H, Oguma T, Tajiri T, Nagasaki T, Kanemitsu Y, Izuhara H, Mishima M, Niimi A, Respiratory physiology & neurobiology, 263, 1 - 8,   2019年05月, 査読有り
  • Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort., Sone K, Oguri T, Uemura T, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A, BMC cancer, 19, (1) ,   2019年03月, 査読有り
  • Independent factors contributing to the daytime and nighttime asthmatic cough refractory to inhaled corticosteroids., Kanemitsu Y, Matsumoto H, Oguma T, Nagasaki T, Ito I, Izuhara Y, Tajiri T, Iwata T, Mishima M, Niimi A, J Investig Allergol Clin Immunol, 29,   2019年, 査読有り
  • Combined measurements of fractional exhaled nitric oxide and nasal nitric oxide levels for assessing upper airway diseases in asthmatic patients., Asano T, Takemura M, Kanemitsu Y, Yokota M, Fukumitsu K, Takeda N, Ichikawa H, Hijikata H, Uemura T, Takakuwa O, Ohkubo H, Maeno K, Ito Y, Oguri T, Nakamura A, Maki Y, Nakamura Y, Suzuki M, Niimi A, The Journal of asthma : official journal of the Association for the Care of Asthma, 55, (3) 300 - 309,   2018年03月, 査読有り
  • A suspected case of inflammatory bronchial polyp induced by bronchial thermoplasty but resolved spontaneously., Takeuchi A, Kanemitsu Y, Takakuwa O, Ito K, Kitamura Y, Inoue Y, Takeda N, Fukumitsu K, Asano T, Fukuda S, Ohkubo H, Takemura M, Maeno K, Ito Y, Oguri T, Niimi A, J Thorac Dis, 10, 678 - 681,   2018年, 査読有り
  • TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer., Takeuchi A, Oguri T, Yamashita Y, Sone K, Fukuda S, Takakuwa O, Uemura T, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A, Anticancer Res, 38, 5489 - 5495,   2018年, 査読有り
  • Prevention of hypoxemia during endobronchial ultrasound-guided transbronchial needle aspiration: Usefulness of high-flow nasal cannula., Takakuwa O, Oguri T, Asano T, Fukuda S, Kanemitsu Y, Uemura T, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A, Respir Investig, 56, 418 - 423,   2018年, 査読有り
  • A Rare Case of Isolated Chronic Cough caused by Pulmonary Lymphangitic Carcinomatosis as a Primary Manifestation of Rectum Carcinoma., Okayama M, Kanemitsu Y, Oguri T, Asano T, Fukuda S, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A, Intern Med, 57, 2709 - 2712,   2018年, 査読有り
  • Bronchial Thermoplasty for Severe Asthmatic Cough., Kanemitsu Y, Takakuwa O, Fukumitsu K, Asano T, Niimi A, Ann Intern Med, 169, 61 - 62,   2018年, 査読有り
  • Sensitization to &ITStaphylococcus aureus&IT enterotoxins in smokers with asthma, Tadao Nagasaki, Hisako Matsumoto, Tsuyoshi Oguma, Isao Ito, Hideki Inoue, Toshiyuki Iwata, Tomoko Tajiri, Yoshihiro Kanemitsu, Yumi Izuhara, Chie Morimoto, Yumi Ishiyama, Hironobu Sunadome, Akio Niimi, Toyohiro Hirai, ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 119, (5) 408 - +,   2017年11月, 査読有り, Background: Sensitization to Staphylococcus aureus enterotoxins (SEs) augments eosinophilic inflammation in asthma. Recent epidemiologic studies demonstrate that sensitization to SEs is increased in healthy smokers; however, there is no evidence on the association between sensitization to SEs and eosinophilic inflammation in smokers with asthma.& para;& para;Objective: To clarify the role of SEs on clinical indexes, including eosinophilic inflammation and lung function in smokers with asthma.& para;& para;Methods: The frequency of atopic sensitization to SEs was examined in adult patients with asthma. In current or ex-smokers with asthma, the association of sensitization to SEs with eosinophilic inflammation, airflow limitation, or treatment steps was determined. Clinical indexes were examined at the first visit, and treatment steps were assessed 6 months after enrollment.& para;& para;Results: Overall, 23 current smokers, 40 ex-smokers, and 118 never smokers with asthma were enrolled. The frequency of sensitization to SEs, but not to other aeroallergens, was significantly higher in current, ex-, and never smokers, in decreasing order. In current or ex-smokers with asthma, patients with sensitization to SEs exhibited higher serum levels of total and specific IgE to aeroallergens, higher blood eosinophil counts, greater airflow limitation, and more severe disease 6 months later than those without sensitization to SE. A longer smoking abstinence period was associated with serum specific IgE levels to SEs, and 3 years was the best cutoff of abstinence period to predict the absence of sensitization to SEs.& para;& para;Conclusion: Sensitization to SEs is increased in smokers with asthma, and it may be a marker of eosinophilic inflammation and severe asthma in smokers with asthma. (C) 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
  • Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs, Akira Takeuchi, Tetsuya Oguri, Kazuki Sone, Keima Ito, Yuki Kitamura, Yoshitsugu Inoue, Takamitsu Asano, Satoshi Fukuda, Yoshihiro Kanemitsu, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi, ANTICANCER RESEARCH, 37, (10) 5771 - 5776,   2017年10月, 査読有り, Background: Tyrosine kinase inhibitors (TKIs) directed against epidermal growth factor receptor (EGFR) are important in the treatment of non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. But little is known regarding the clinical value of serum tumor marker levels measured prior to treatment. Patients and Methods: We retrospectively reviewed 95 patients with advanced NSCLC treated with EGFR-TKIs, and inspected the relationship between serum tumor marker levels and clinical outcome. Results: Forty-three patients with an elevated serum level of cytokeratin 19 fragment (CYFRA 21-1) had shorter progression-free (PFS) and overall (OS) survival than 52 patients with normal serum CYFRA 21-1 levels (99 vs. 123.5 days p=0.011; and 385 vs. 607 days, respectively, p=0.001). Regardless of EGFR mutation status, patients had shorter progression-free survival when serum CYFRA 21-1 was elevated. Conclusion: Serum CYFRA 21-1 level may be a predictive factor for patients with NSCLC treated with EGFR-TKIs, regardless of EGFR mutation status.
  • Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients, Kazuki Sone, Tetsuya Oguri, Keima Ito, Yuki Kitamura, Yoshitsugu Inoue, Akira Takeuchi, Satoshi Fukuda, Osamu Takakuwa, Ken Maeno, Takamitsu Asano, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi, ANTICANCER RESEARCH, 37, (9) 5125 - 5131,   2017年09月, 査読有り, Background/Aim: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients. Patients and Methods: We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA). Results: The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p= 0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p< 0.001; median OS, 579 vs. 255 days, p= 0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS. Conclusion: Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients.
  • Optimal cut-off value and clinical usefulness of the Adherence Starts with Knowledge-12 in patients with asthma taking inhaled corticosteroids, Masaya Takemura, Masayuki Nishio, Kensuke Fukumitsu, Norihisa Takeda, Hiroya Ichikawa, Takamitsu Asano, Hiroki Tomita, Yoshihiro Kanemitsu, Kosho Yoshikawa, Akio Niimi, JOURNAL OF THORACIC DISEASE, 9, (8) 2350 - 2359,   2017年08月, 査読有り, Background: Non-adherence to inhalation regimens is common in asthmatic patients. The Adherence Starts with Knowledge-12 (ASK-12) survey was developed to detect and address patient-specific barriers to medication adherence. Our objective is to investigate the clinical usefulness of the ASK-12 for assessing and addressing adherence to inhalation therapy in asthma. Methods: The ASK-12 was administered to 138 asthmatic patients. Using pharmacy-refill data, we examined the cut-off value of the ASK-12 to identify patients who were non-adherent to inhalation regimens and identify factors associated with non-adherence. To verify the usefulness of the ASK-12, inhalation regimens were prospectively switched to less-expensive and simpler (once-daily) dosing regimens in eight non-adherent asthmatic patients who reported specific-barriers in "inconvenience of twice-daily inhaler use" and "cost". Results: Valid responses were received from 114 (82.6%) patients. A significant correlation was found between pharmacy-refill rates and the ASK-12 total score (r=-0.55, P < 0.0001). The optimal cut-off value of the ASK-12 total score to discriminate non-adherent patients (defined by pharmacy-refill rate < 80%) was 23, with 71.4% specificity and 93.3% sensitivity. Using this value, 52 (45.6%) patients were classified as non-adherent. Univariate followed by multivariate analysis identified younger age as a predictor of non-adherence to inhalation regimens (odds ratio, 2.67; 95% CI, -0.95 to -0.06; P=0.027). Switching inhaled medicines in eight patients resulted in significant improvements in both ASK-12 scores and asthma control. Conclusions: The ASK-12 is a brief, practical, and clinically useful measure for assessing and addressing adherence to inhalation regimens in asthma.
  • IL4Rα and ADAM33 as genetic markers in asthma exacerbations and type-2 inflammatory endotype., Sunadome H, Matsumoto H, Petrova G, Kanemitsu Y, Tohda Y, Horiguchi T, Kita H, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Hirota T, Tamari M, Yokoyama T, Niimi A, Izuhara K, Mishima M, Clin Exp Allergy, 47, (8) 998 - 1006,   2017年08月, 査読有り
  • Reply: Response to Risks and Cough-Aggravating Factors in Prolonged Cough., Matsumoto H, Nagasaki T, Kanemitsu Y, Niimi A, Tabara Y, Annals of the American Thoracic Society, 14, (7) 1232 - 1233,   2017年07月, 査読有り
  • Risks and Cough-Aggravating Factors in Prolonged Cough. Epidemiological Observations from the Nagahama Cohort Study., Matsumoto H, Izuhara Y, Niimi A, Tabara Y, Nagasaki T, Kanemitsu Y, Murase K, Oguma T, Ito I, Muro S, Sekine A, Matsuda F, Kosugi S, Nakayama T, Chin K, Mishima M, Nagahama Study Collaboration Group, Annals of the American Thoracic Society, 14, (5) 698 - 705,   2017年05月, 査読有り
  • Risks and Cough-Aggravating Factors in Prolonged Cough Epidemiological Observations from the Nagahama Cohort Study, Hisako Matsumoto, Yumi Izuhara, Akio Niimi, Yasuharu Tabara, Tadao Nagasaki, Yoshihiro Kanemitsu, Kimihiko Murase, Tsuyoshi Oguma, Isao Ito, Shigeo Muro, Akihiro Sekine, Fumihiko Matsuda, Shinji Kosugi, Takeo Nakayama, Kazuo Chin, Michiaki Mishima, ANNALS OF THE AMERICAN THORACIC SOCIETY, 14, (5) 698 - 705,   2017年05月, 査読有り, Rationale: Chronic cough hypersensitivity, a potentially important concept of chronic or prolonged cough, is featured by heightened cough response to low-intensity stimuli, which may be generated in the absence of airflow limitations or allergic conditions. However, there is little epidemiological evidence to support this. Objectives: In this large-scale community survey, we aimed to determine risks and cough-aggravating factors of prolonged cough while focusing on serum IgE levels. Methods: Prevalence of prolonged cough, defined as cough lasting 3 weeks or longer, was determined in 9,804 residents from a baseline measurement of the Nagahama Cohort Study, conducted from 2008 to 2010. Risk assessment of prolonged cough was confined to subjects without asthma (n = 9,402). Afollow-up measurement of the Nagahama Studywas successively conducted from 2013 to 2015, recruiting the same residents living inNagahamaCity, Japan (n = 8,292). Validation analysis was performed in the follow-up measurement. Results: In a baseline measurement, prolonged cough was reported by 9.5% of subjects without asthma and 32.3% of subjects with asthma. In subjects without asthma, various cough-aggravating factors were associated with prolonged cough. On the multivariate analysis, several cough-aggravating factors, including nighttime or early morning, weather, pollen season, and common cold, were associated with prolonged cough, independent of female sex, younger age, chronic obstructive pulmonary disease, postnasal drip, daytime sputum, and lower serum total IgE. Serum-specific IgE levels against Japanese cedar pollen were significantly higher in subjects who responded "yes" to " cough in the pollen season" than in those who did not respond, whereas, among subjects who responded "yes" to "cough in the pollen season," prolonged coughers showed lower serum IgE levels against Japanese cedar pollen than temporal coughers. Validation analysis in a follow-up measurement confirmed the associations between prolonged cough and cough-aggravating factors observed in the baseline measurement. Conclusions: The presence of several cough-aggravating factors in the absence of severe allergic conditions may support the presence of cough hypersensitivity.
  • Serum Periostin as a Biomarker for Comorbid Chronic Rhinosinusitis in Patients with Asthma, Takamitsu Asano, Yoshihiro Kanemitsu, Masaya Takemura, Makoto Yokota, Kensuke Fukumitsu, Norihisa Takeda, Hiroya Ichikawa, Takehiro Uemura, Osamu Takakuwa, Hirotsugu Ohkubo, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Yumi Maki, Junya Ono, Shoichiro Ohta, Yoshihisa Nakamura, Kenji Izuhara, Motohiko Suzuki, Akio Niimi, ANNALS OF THE AMERICAN THORACIC SOCIETY, 14, (5) 667 - 675,   2017年05月, 査読有り, Rationale: Periostin is a matricellular protein that is involved in the pathophysiology of allergic rhinitis, chronic rhinosinusitis, and asthma. Associations of serum periostin with systemic and airway eosinophilic inflammation and comorbid chronic rhinosinusitis in patients with asthma have been demonstrated. Although serum periostin is positioned as a marker of helper T cell 2 immune responses, its implication regarding the presence of comorbid upper airway diseases in patients with asthma remains unclear. Objectives: To investigate the utility of serum periostin as a diagnostic biomarker for upper airway disease in patients with asthma. Methods: Weprospectively enrolled 65 patients with stable asthma, 20 without upper airway disease, 22 with rhinitis, and 23 with chronic rhinosinusitis (13 with nasal polyps, 10 without). Serum periostin, eotaxin, total IgE, fractional exhaled nitric oxide, and blood and sputum eosinophil levels were measured and compared between upper airway disease subtypes. We evaluated the utility of each biomarker in detecting upper airway disease, associations among the biomarkers, and severity of upper airway disease as measured by the Lund-Mackay score for sinus computed tomography. Results: Serum periostin levels were higher in patients with asthma who had chronic rhinosinusitis (109.6647.4 ng/ml) than in those without upper airway disease (83.2622.9 ng/ml) (P = 0.04). Serum periostin levels in patients with asthma who had chronic rhinosinusitis and nasal polyps were significantly higher (130.0646.6ng/ml) than in those without nasal polyps (87.9637.7 ng/ml) (P = 0.001). Serum periostin levels were not associated with the presence or the severity of rhinitis. In contrast, receiver operating characteristic curve analyses showed moderate diagnostic accuracy for detecting chronic rhinosinusitis (areaunder the curve, 0.71; P = 0.01) andhigh accuracy for chronic rhinosinusitiswith nasal polyps (area under the curve, 0.86; P = 0.0002). When we compared patients with asthma who had comorbid chronic rhinosinusitis and nasal polyps with patients with asthma without these comorbidities, we found serum periostin to be the sole biomarker among those tested for detecting the presence of nasal polyps. Serum periostin was also the sole biomarker that significantly correlated with Lund-Mackay score in patients with chronic rhinosinusitis (r = 0.44; P = 0.04). Conclusions: Serum periostin is useful for detecting chronic rhinosinusitis with nasal polyps and predicting radiological chronic rhinosinusitis severity in patients with asthma.
  • Diagnostic utility of fractional exhaled nitric oxide in prolonged and chronic cough according to atopic status, Takamitsu Asano, Masaya Takemura, Kensuke Fukumitsu, Norihisa Takeda, Hiroya Ichikawa, Hisatoshi Hijikata, Yoshihiro Kanemitsu, Takehiro Uemura, Osamu Takakuwa, Hirotsugu Ohkubo, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Atsushi Nakamura, Akio Niimi, ALLERGOLOGY INTERNATIONAL, 66, (2) 344 - 350,   2017年04月, 査読有り, Background: Cough-variant asthma (CVA) and cough-predominant asthma (CPA) are the major causes of persistent cough in Japan. The utility of fractional exhaled nitric oxide (FeNO) measurement in the differential diagnosis of persistent cough has been reported, but the influence of atopic status, which is associated with higher FeNO levels, on the diagnostic utility of FeNO has been unknown. Methods: We retrospectively analyzed 105 non-smoking patients with prolonged and chronic cough that were not treated with corticosteroids and anti-leukotrienes. Results: CPA was diagnosed in 37 patients, CVA in 40, and non-asthmatic cough (NAC) in 28. FeNO levels were significantly higher in the CPA [35.8 (7.0-317.9) ppb] and CVA [24.9 (3.1-156.0) ppb] groups than in the NAC group [18.2 (6.9-49.0) ppb] (p < 0.01 by Kruskal Wallis test). The optimal cut-off for distinguishing asthmatic cough (AC; CPA and CVA) from NAC was 29.2 ppb [area under the curve (AUC) 0.74, p < 0.01]. Ninety-one percent of subjects with FeNO levels >= 29.2 ppb had AC. Meanwhile, 40% of AC patients had FeNO levels <29.2 ppb. Stratified cut-off levels were 31.1 ppb (AUC 0.83) in atopic subjects vs. 19.9 ppb (AUC 0.65) in non-atopic subjects (p = 0.03 for AUC). Conclusions: Although high FeNO levels suggested the existence of AC, lower FeNO levels had limited diagnostic significance. Atopic status affects the utility of FeNO levels in the differential diagnosis of prolonged and chronic cough. Copyright (C) 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
  • CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy, Kazuki Sone, Tetsuya Oguri, Makoto Nakao, Yusuke Kagawa, Ryota Kurowaka, Hiromi Furuta, Satoshi Fukuda, Takehiro Uemura, Osamu Takakuwa, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Hidefumi Sato, Hideki Muramatsu, Akio Niimi, ANTICANCER RESEARCH, 37, (2) 935 - 939,   2017年02月, 査読有り, Background: Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. Patients and Methods: We retrospectively screened 100 chemotherapy-naive patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA). Results: Sixty one patients with a high CYFRA 21-1 level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level (median progression-free survival=127 days vs. 191 days, respectively; p=0.046; median overall survival=360 days vs. 781 days, respectively, p<0.001). Serum CEA level was not related to survival. Conclusion: Serum CYFRA 21-1 level is a predictive and prognostic marker in patients with NSCLC treated with pemetrexed plus a platinum-derivative.
  • Staphylococcus aureus enterotoxin sensitization involvement and its association with the CysLTR1 variant in different asthma phenotypes, Hisako Matsumoto, Yoshihiro Kanemitsu, Tadao Nagasaki, Yuji Tohda, Takahiko Horiguchi, Hideo Kita, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Yumi Izuhara, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Junya Ono, Shoichiro Ohta, Tomomitsu Hirota, Takahisa Kawaguchi, Mayumi Tamari, Tetsuji Yokoyama, Yasuharu Tabara, Fumihiko Matsuda, Kenji Izuhara, Akio Niimi, Michiaki Mishima, ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 118, (2) 197 - 203,   2017年02月, 査読有り, Background: Sensitization to Staphylococcus aureus enterotoxin (SE) is a known risk factor for asthma susceptibility and severity. However, how SE sensitization is involved in asthma, particularly nonatopic asthma and/or late-onset asthma, remains uncertain. Objective: To clarify the involvement of SE sensitization in nonatopic and/or late-onset asthma and its association with a polymorphism of the cysteinyl leukotriene receptor 1 gene (CysLTR1), which was examined because CysLT signaling is closely associated with late-onset eosinophilic asthma. Methods: We assessed associations between sensitization to SE (A and/or B) and clinical indexes in 224 patients with asthma (mean age, 62.3 years; 171 women) from a cohort of the Kinki Hokuriku Airway Disease Conference, particularly those with nonatopic asthma (not sensitized to common aeroallergens) and/or late-onset asthma. Associations between SE sensitization and CysLTR1 polymorphism (rs2806489), a potential regulatory variant for atopic predisposition in women, were also assessed in a sex-stratified manner. Results: A total of 105 patients (47%) with asthma were sensitized to SE. Among patients with nonatopic asthma (n = 67) or with late-onset asthma (n = 124), those sensitized to SE had significantly higher serum total IgE and periostin levels than those not sensitized. In nonatopic patients, a rapid decrease in forced expiratory volume in 1 second was associated with SE sensitization. In women with asthma, rs2806489 was associated with sensitization to SEB and age at asthma onset. Conclusion: SE sensitization contributes to TH2 inflammation in nonatopic and/or late-onset asthma. In women with asthma, the CysLTR1 variant might be associated with sensitization to SEB and age at asthma onset. (C) 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
  • Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report., Uemura T, Oguri T, Okayama M, Furuta H, Kanemitsu Y, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A, Mol Clin Oncol, 6, 525 - 528,   2017年, 査読有り
  • Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report., Takakuwa O, Oguri T, Uemura T, Sone K, Fukuda S, Okayama M, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Maeno K, Niimi A, Mol Clin Oncol, 7, 383 - 385,   2017年, 査読有り
  • Three-dimensional imaging forced oscillation technique to assess position-dependent airway obstruction in relapsing polychondritis: A case report., Kamada T, Ito I, Kanemitsu Y, Sato S, Matsumoto H, Niimi A, Mishima M, Respir Investig, 55, 69 - 73,   2017年, 査読有り
  • Association of interleukin 1 receptor-like 1 gene polymorphisms with eosinophilic phenotype in Japanese adults with asthma., Inoue H, Ito I, Niimi A, Matsumoto H, Oguma T, Tajiri T, Iwata T, Nagasaki T, Kanemitsu Y, Morishima T, Hirota T, Tamari M, Wenzel SE, Mishima M, Respir Investig, 55, 338 - 347,   2017年, 査読有り
  • EBUS-TBNAが診断に有用であった縦隔リンパ節腫大を伴う肺クリプトコッカス症の1例, 堀内 実, 高桑 修, 市川 博也, 岡山 未奈実, 金光 禎寛, 上村 剛大, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 鉄也, 中村 敦, 新実 彰男, 気管支学, 39, (1) 58 - 63,   2017年01月, 査読有り
  • A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer., Fukuda S, Oguri T, Kunii E, Sone K, Uemura T, Takakuwa O, Maeno K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A, Lung Cancer, 102, 15 - 20,   2016年12月, 査読有り
  • Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis (vol 11, e0152505, 2016), Hirotsugu Ohkubo, Yoshihiro Kanemitsu, Takehiro Uemura, Osamu Takakuwa, Masaya Takemura, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Nobukata Kazawa, Ryuji Mikami, Akio Niimi, PLOS ONE, 11, (8) ,   2016年08月, 査読有り
  • Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma, Yoshihiro Kanemitsu, Akio Niimi, Hisako Matsumoto, Toshiyuki Iwata, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Tadao Nagasaki, Yumi Izuhara, Guergana Petrova, Surinder S. Birring, Michiaki Mishima, ALLERGOLOGY INTERNATIONAL, 65, (3) 320 - 326,   2016年07月, 査読有り, Background: Gastroesophageal reflux disease (GERD) is known as a common comorbidity of asthma and chronic cough. The impact of GERD symptoms on cough-specific quality of life (QoL) in patients with asthmatic cough is poorly understood. The aim of this study is to determine the association of GERD symptoms with cough-specific quality of life in patients with cough variant asthma (CVA) using the Leicester Cough Questionnaire (LCQ). Methods: A total of 172 consecutive patients (121 females) with mean cough duration of 45.1 months (range 2-480 months) completed the Japanese version of the LCQ. The Frequency Scale for the Symptoms of Gastroesophageal reflux was administered to assess symptoms of acid-reflux and dysmotility. A range of clinical variables that may determine cough-specific QoL (LCQ) were estimated. Results: The mean LCQ scores was 12.9 (SD 3.5), consistent with severe impairment in QoL. Female gender, symptoms of gastroesophageal dysmotility, sensitization to allergens (house dust and Japanese cedar pollen) and the number of sensitized allergens were associated with lower LCQ scores (i.e. impaired cough-specific QoL) in univariate regression analysis. Acid-reflux symptoms, airway hyper-responsiveness, fractional exhaled nitric oxide, and sensitization to molds were unrelated to the LCQ score. After adjustment for gender, symptoms of gastroesophageal dysmotility was the only significant determinant of impaired cough-specific QoL accounting for 23% of the variance. Conclusions: Cough-specific QoL is severely impaired in patients with CVA. Symptoms of gastroesophageal dysmotility are an independent predictor of cough-specific QoL of patients with CVA. Copyright (C) 2016, Japanese Society of Allergology.
  • Mouth breathing, another risk factor for asthma: the Nagahama Study, Y. Izuhara, H. Matsumoto, T. Nagasaki, Y. Kanemitsu, K. Murase, I. Ito, T. Oguma, S. Muro, K. Asai, Y. Tabara, K. Takahashi, K. Bessho, A. Sekine, S. Kosugi, R. Yamada, T. Nakayama, F. Matsuda, A. Niimi, K. Chin, M. Mishima, ALLERGY, 71, (7) 1031 - 1036,   2016年07月, 査読有り, Background: Allergic rhinitis, a known risk factor for asthma onset, often accompanies mouth breathing. Mouth breathing may bypass the protective function of the nose and is anecdotally considered to increase asthma morbidity. However, there is no epidemiological evidence that mouth breathing is independently associated with asthma morbidity and sensitization to allergens. In this study, we aimed to clarify the association between mouth breathing and asthma morbidity and allergic/eosinophilic inflammation, while considering the effect of allergic rhinitis. Methods: This community-based cohort study, the Nagahama Study, contained a self-reporting questionnaire on mouth breathing and medical history, blood tests, and pulmonary function testing. We enrolled 9804 general citizens of Nagahama City in the Shiga Prefecture, Japan. Results: Mouth breathing was reported by 17% of the population and was independently associated with asthma morbidity. The odds ratio for asthma morbidity was 1.85 (95% CI, 1.27-2.62) and 2.20 (95% CI, 1.72-2.80) in subjects with mouth breathing alone and allergic rhinitis alone, which additively increased to 4.09 (95% CI, 3.01-5.52) when mouth breathing and allergic rhinitis coexisted. Mouth breathing in nonasthmatics was a risk for house dust mite sensitization, higher blood eosinophil counts, and lower pulmonary function after adjusting for allergic rhinitis. Conclusion: Mouth breathing may increase asthma morbidity, potentially through increased sensitization to inhaled allergens, which highlights the risk of mouthbypass breathing in the ` one airway, one disease' concept. The risk of mouth breathing should be well recognized in subjects with allergic rhinitis and in the general population.
  • Organic cation transporter 6 directly confers resistance to anticancer platinum drugs., Oguri T, Kunii E, Fukuda S, Sone K, Uemura T, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A, Biomed Rep, 5, 639 - 643,   2016年, 査読有り
  • "Cold air" and/or "talking" as cough triggers, a sign for the diagnosis of cough variant asthma., Kanemitsu Y, Matsumoto H, Osman N, Oguma T, Nagasaki T, Izuhara Y, Ito I, Tajiri T, Iwata T, Niimi A, Mishima M, Respir Investig, 54, 413 - 418,   2016年, 査読有り
  • CT-assessed large airway involvement and lung function decline in eosinophilic asthma: The association between induced sputum eosinophil differential counts and airway remodeling, Hideki Inoue, Isao Ito, Akio Niimi, Hisako Matsumoto, Hirofumi Matsuoka, Makiko Jinnai, Tomoshi Takeda, Tsuyoshi Oguma, Kojiro Otsuka, Hitoshi Nakaji, Tomoko Tajiri, Toshiyuki Iwata, Tadao Nagasaki, Yoshihiro Kanemitsu, Michiaki Mishima, JOURNAL OF ASTHMA, 53, (9) 914 - 921,   2016年, 査読有り, Objectives: Eosinophilic asthma (EA) is a distinct clinical phenotype characterized by eosinophilic airway inflammation and airway remodeling. Few studies have used computed tomography (CT) scanning to assess the association between sputum eosinophil differential counts and airway involvement. We aimed to investigate the clinical characteristics and airway involvement of EA, and to examine the correlation between induced sputum eosinophil differential counts and CT-assessed airway remodeling. Methods: We retrospectively divided 63 patients with stable asthma receiving inhaled corticosteroids into 2 groups: 26 patients with EA (sputum eosinophil >3%) and 37 patients with non-eosinophilic asthma (NEA). Clinical measurements such as spirometry, fractional exhaled nitric oxide levels (FeNO), and CT-assessed indices of airway involvement were compared between the groups. Multivariate analysis was performed to identify determinants of the percentage of wall area (WA%). Results: The EA group had significantly longer asthma duration, lower pulmonary function, and higher FeNO than the NEA group. Also, the EA group had higher WA% and smaller airway luminal area than the NEA group. Sputum eosinophil differential counts and WA% were positively correlated. The multivariate linear regression analysis showed that the factors associated with WA% included sputum eosinophil differential counts, age, and body mass index. However, asthma duration was not associated with WA%. Our CT-assessed findings demonstrated large airway involvement in EA, and we observed a positive association between induced sputum eosinophil differential counts and WA%. Conclusions: The findings indicate that induced sputum eosinophil differential counts may be associated with airway remodeling in patients with stable asthma.
  • Mechanical Stimulation by Postnasal Drip Evokes Cough., Iwata T, Ito I, Niimi A, Ikegami K, Marumo S, Tanabe N, Nakaji H, Kanemitsu Y, Matsumoto H, Kamei J, Setou M, Mishima M, PLoS One, 10,   2015年, 査読有り
  • Using Exhaled Nitric Oxide and Serum Periostin as a Composite Marker to Identify, Severe/Steroid-Insensitive Asthma, Tadao Nagasaki, Hisako Matsumoto, Yoshihiro Kanemitsu, Kenji Izuhara, Yuji Tohda, Takahiko Horiguchi, Hideo Kita, Keisuke Tomii, Masaki Fujimura, Akihito Yokoyama, Yasutaka Nakano, Soichiro Hozawa, Isao Ito, Tsuyoshi Oguma, Yumi Izuhara, Tomoko Tajiri, Toshiyuki Iwata, Junya Ono, Shoichiro Ohta, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 190, (12) 1449 - 1452,   2014年12月, 査読有り
  • Pathophysiological characteristics of asthma in the elderly: a comprehensive study, Hideki Inoue, Akio Niimi, Tomoshi Takeda, Hisako Matsumoto, Isao Ito, Hirofumi Matsuoka, Makiko Jinnai, Kojiro Otsuka, Tsuyoshi Oguma, Hitoshi Nakaji, Tomoko Tajiri, Toshiyuki Iwata, Tadao Nagasaki, Yoshihiro Kanemitsu, Kazuo Chin, Michiaki Mishima, ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 113, (5) 527 - 533,   2014年11月, 査読有り, Background: Comprehensive studies of the pathophysiologic characteristics of elderly asthma, including predominant site of disease, airway inflammation profiles, and airway hyperresponsiveness, are scarce despite their clinical importance. Objective: To clarify the pathophysiologic characteristics of elderly patients with asthma. Methods: Patients older than 65 years (elderly; n = 45) vs those no older than 65 years (nonelderly; n = 67) were retrospectively analyzed by spirometry, computed tomographic indices of large airway wall thickness and small airway involvement (air trapping), impulse oscillation measurements, exhaled nitric oxide levels, blood and induced sputum cell differentials, methacholine airway responsiveness, and total and specific serum IgE levels. Results: Elderly patients with asthma had significantly lower values for forced expiration volume in 1 second, mid-forced expiratory flow (percentage predicted), and ratio of forced expiration volume in 1 second to forced vital capacity than nonelderly patients with asthma (median 81.2% vs 88.8%, P = .02; 50.9% vs 78.6%, P = .03; 0.72 vs 0.78, P = .001, respectively). In computed tomographic measurements, elderly patients with asthma had significantly greater airway wall thickening and air trapping than nonelderly patients. Impulse oscillation measurements indicated that elderly patients with asthma showed significantly greater resistance at 5 Hz (used as an index of total airway resistance), greater decrease in resistance from 5 to 20 Hz, a higher ratio of decrease in resistance from 5 to 20 Hz to resistance at 5 Hz, higher integrated area between 5 Hz and frequency of resonance, greater frequency of resonance, and lower reactance at a frequency of 5 Hz (potential markers of small airway disease) than nonelderly patients. There were no significant differences in blood or sputum cell differentials, exhaled nitric oxide, or methacholine airway responsiveness between the 2 groups. Total serum IgE levels and positive rates of specific IgE antibodies against several allergens were significantly lower in elderly than in nonelderly patients with asthma. Conclusion: Based on spirometric, computed tomographic, and impulse oscillation analyses, elderly patients with asthma have greater involvement of small and large airways than nonelderly patients with asthma. (C) 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
  • Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study, Tomoko Tajiri, Akio Niimi, Hisako Matsumoto, Isao Ito, Tsuyoshi Oguma, Kojiro Otsuka, Tomoshi Takeda, Hitoshi Nakaji, Hideki Inoue, Toshiyuki Iwata, Tadao Nagasaki, Yoshihiro Kanemitsu, Yumi Izuhara, Michiaki Mishima, ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 113, (4) 470 - U282,   2014年10月, 査読有り, Background: Omalizumab, a humanized anti-IgE monoclonal antibody, is reportedly an effective treatment for severe allergic asthma. However, there have been few comprehensive analyses of its efficacy, including assessments of small airways or airway remodeling. Objective: To comprehensively evaluate the efficacy of omalizumab, including its effects on small airways and airway remodeling, in adult patients with severe refractory asthma. Methods: In this prospective, time-series, single-arm observational study, 31 adult patients with severe refractory asthma despite the use of multiple controller medications, including high-dose inhaled corticosteroids (1,432 +/- 581 mu g/d of fluticasone propionate equivalent), were enrolled. Clinical variables, including Asthma Quality of Life Questionnaire, asthma exacerbations, exhaled nitric oxide, pulmonary function, methacholine airway responsiveness, induced sputum, and chest computed tomogram, were assessed at baseline and after 16 and 48 weeks of treatment with omalizumab. Results: Twenty-six of the 31 patients completed 48 weeks of treatment. For these patients, Asthma Quality of Life Questionnaire scores and peak expiratory flow values significantly and continuously improved throughout the 48 weeks (P < .001 for all comparisons). Unscheduled physician visits, asthma exacerbations requiring systemic corticosteroids, fractional exhaled nitric oxide at 50 mL/s and alveolar nitric oxide levels, sputum eosinophil proportions, and airway-wall thickness as assessed by computed tomography significantly decreased at 48 weeks (P < .05 for all comparisons). Conclusion: Omalizumab was effective for adult patients with severe refractory asthma. Omalizumab may have anti-inflammatory effects on small airways and reverse airway remodeling. (C) 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
  • Osteopontin and Periostin Are Associated with a 20-Year Decline of Pulmonary Function in Patients with Asthma, Yoshihiro Kanemitsu, Isao Ito, Akio Niimi, Kenji Izuhara, Shoichiro Ohta, Junya Ono, Toshiyuki Iwata, Hisako Matsumoto, Michiaki Mishima, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 190, (4) 472 - 474,   2014年08月, 査読有り
  • Factors Contributing to an Accelerated Decline in Pulmonary Function in Asthma, Yoshihiro Kanemitsu, Hisako Matsumoto, Michiaki Mishima, ALLERGOLOGY INTERNATIONAL, 63, (2) 181 - 188,   2014年06月, 査読有り, Patients with asthma show a steeper age-related decline in pulmonary function than healthy subjects, which is often alleviated after the initiation of treatment with inhaled corticosteroids (ICS). However, there still are patients who develop irreversible airflow limitations despite receiving adequate ICS treatment. The identification of the characteristics of such patients and biomarkers of progression for airflow limitation, a functional consequence of airway remodeling, is considered important in the management of asthma. A variety of biomarkers are associated with the forced expiratory volume in 1 S (FEV1) in asthma in a cross-sectional fashion. However, few biomarkers are known to reflect the decline in pulmonary function, particularly in patients with asthma who receive ICS treatment. Recently periostin, a matricellular protein that prolongs Th2/eosinophilic inflammation and reflects airway remodeling, was reported to be detected in serum. In a Kinki Hokuriku Airway disease Conference multicenter cohort study, we demonstrated that among several serum markers, high serum periostin level, particularly >= 95 ng/mL, was the only marker associated with a greater annual decline in FEV1 and a decline in FEV1 of mL.yr(-1). A variant (rs9603226) of the POSTN gene that encodes periostin was also involved in the frequency of a decline in FEV1 of 30 mL.yr(-1). Our results suggest that the serum periostin level is a useful marker reflecting pulmonary function decline in patients with asthma receiving ICS.
  • Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes, Tadao Nagasaki, Hisako Matsumoto, Yoshihiro Kanemitsu, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 133, (5) 1474 - U406,   2014年05月, 査読有り
  • GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids, Y. Izuhara, H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, M. Fujimura, N. Ohkura, K. Tomita, A. Yokoyama, H. Ohnishi, Y. Nakano, T. Oguma, S. Hozawa, T. Nagasaki, I. Ito, T. Oguma, H. Inoue, T. Tajiri, T. Iwata, J. Ono, S. Ohta, M. Tamari, T. Hirota, T. Yokoyama, A. Niimi, M. Mishima, ALLERGY, 69, (5) 668 - 673,   2014年05月, 査読有り, Background In steroid-naive patients with asthma, several gene variants are associated with a short-term response to inhaled corticosteroid (ICS) treatment; this has mostly been observed in Caucasians. However, not many studies have been conducted for other ethnicities. Here, we aimed to determine the relationship between the annual decline in forced expiratory flow volume in one second (FEV1) and the variant of the glucocorticoid-induced transcript 1 gene (GLCCI1) in Japanese patients with asthma receiving long-term ICS treatment, taking into account the effect of high serum periostin levels, a known association factor of pulmonary function decline and a marker of refractory eosinophilic/Th2 inflammation. Methods In this study, 224 patients with asthma receiving ICS treatment for at least 4years were enrolled. The effects of single-nucleotide polymorphisms (SNPs) in GLCCI1, stress-induced phosphoprotein 1 (STIP1), and T gene on the decline in FEV1 of 30ml/year or greater were determined. Results Besides the known contributing factors, that is, the most intensive treatment step, ex-smoking, and high serum periostin levels (>= 95ng/ml), the GG genotype of GLCCI1 rs37973, and not other SNPs, was independently associated with a decline in FEV1 of 30ml/year or greater. When patients were stratified according to their serum periostin levels, the GG genotype of rs37973 was significantly associated with blood eosinophilia (>= 250/mu l) in the high serum periostin group. Conclusions A GLCCI1 variant is a risk factor of pulmonary function decline in Japanese patients with asthma receiving long-term ICS treatment. Thus, GLCCI1 may be associated with response to ICS across ethnicities.
  • アダリムマブ投与中にレジオネラ肺炎を呈し、血栓性血小板減少性紫斑病を併発した1例, 西原 祐美, 金光 禎寛, 佐渡 紀克, 片山 優子, 深田 寛子, 北 英夫, 日本呼吸器学会誌, 2, (5) 598 - 602,   2013年09月, 査読有り
  • Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids, Yoshihiro Kanemitsu, Hisako Matsumoto, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Tadao Nagasaki, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Mayumi Tamari, Tomomitsu Hirota, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 132, (2) 305 - +,   2013年08月, 査読有り, Background: Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. Objective: We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. Methods: Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. Results: High serum periostin levels (>= 95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). Conclusions: Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.
  • Association of Eosinophilic Inflammation with FKBP51 Expression in Sputum Cells in Asthma, Tomoko Tajiri, Hisako Matsumoto, Akio Niimi, Isao Ito, Tsuyoshi Oguma, Hitoshi Nakaji, Hideki Inoue, Toshiyuki Iwata, Tadao Nagasaki, Yoshihiro Kanemitsu, Guergana Petrova, Michiaki Mishima, PLOS ONE, 8, (6) ,   2013年06月, 査読有り, Background: Airway eosinophilia is a predictor of steroid responsiveness in steroid-naive asthma. However, the relationship between airway eosinophilia and the expression of FK506-binding protein 51 (FKBP51), a glucocorticoid receptor cochaperone that plays a role in steroid insensitivity in asthma, remains unknown. Objective: To evaluate the relationship between eosinophilic inflammation and FKBP51 expression in sputum cells in asthma. Methods: The FKBP51 mRNA levels in sputum cells from steroid-naive patients with asthma (n = 31) and stable asthmatic patients on inhaled corticosteroid (ICS) (n = 28) were cross-sectionally examined using real-time PCR. Associations between FKBP51 levels and clinical indices were analyzed. Results: In steroid-naive patients, the FKBP51 levels were negatively correlated with eosinophil proportions in blood (r = -0.52) and sputum (r = -0.57), and exhaled nitric oxide levels (r = -0.42) (all p<0.05). No such associations were observed in patients on ICS. In steroid-naive patients, improvement in forced expiratory volume in one second after ICS initiation was correlated with baseline eosinophil proportions in blood (r = 0.74) and sputum (r = 0.76) and negatively correlated with FKBP51 levels (r = -0.73) (all p<0.0001) (n = 20). Lastly, the FKBP51 levels were the lowest in steroid-naive asthmatic patients, followed by mild to moderate persistent asthmatic patients on ICS, and the highest in severe persistent asthmatic patients on ICS (p<0.0001). Conclusions: Lower FKBP51 expression in sputum cells may reflect eosinophilic inflammation and glucocorticoid responsiveness in steroid-naive asthmatic patients.
  • Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation, T. Nagasaki, H. Matsumoto, H. Nakaji, A. Niimi, I. Ito, T. Oguma, S. Muro, H. Inoue, T. Iwata, T. Tajiri, Y. Kanemitsu, M. Mishima, CLINICAL AND EXPERIMENTAL ALLERGY, 43, (6) 608 - 615,   2013年06月, 査読有り, Background Epidemiological studies have shown that smoking increases the propensity for atopy and asthma. However, the effects of smoking on atopy and eosinophilic inflammation in asthmatics, including the elderly, remain unknown. Objective To determine the effects of smoking on serum immunoglobulin E (IgE) levels and eosinophilic inflammation in asthmatics of all ages. Methods The associations of serum IgE levels, blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels with smoking and age in steroid-naive asthmatics were cross-sectionally assessed (n=307). Levels of sputum eosinophil and thymic stromal lymphopoietin (TSLP) that promotes Th2 inflammation were also analysed. Current smokers were excluded when analysing contributing factors of FeNO. Results Levels of serum IgE, blood eosinophil and FeNO decreased with increasing age in never-smokers, whereas decrease in serum IgE levels with increasing age was not observed in current smokers. In addition, current smoking was associated with higher blood eosinophil counts. In atopic asthmatics, age-related declines in serum IgE levels were less steep in ex-smokers than in never-smokers, and atopic ex-smokers with asthma showed higher blood eosinophil counts and higher FeNO irrespective of age. Lastly, sputum TSLP levels were associated with sputum eosinophil proportions and pack-years. Current and ex-smokers had higher TSLP levels than never-smokers. Conclusions and Clinical Relevance In steroid-naive asthmatics, smoking may attenuate the age-related decrease in IgE levels and maintain eosinophilic inflammation, in which TSLP may be involved.
  • Effects of 24-week add-on treatment with ciclesonide and montelukast on small airways inflammation in asthma, Hitoshi Nakaji, Guergana Petrova, Hisako Matsumoto, Toshiyuki Iwata, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Tadao Nagasaki, Yoshihiro Kanemitsu, Akio Niimi, Michiaki Mishima, ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 110, (3) 198 - +,   2013年03月, 査読有り, Background: Eosinophilic inflammation of the small airways is a key process in asthma that often smolders in treated patients. The long-term effects of add-on therapy on the persistent inflammation in the small airways remain unknown. Objective: To examine the effects of add-on therapy with either ciclesonide, an inhaled corticosteroid with extrafine particles, or montelukast on small airway inflammation. Methods: Sixty patients with stable asthma receiving inhaled corticosteroid treatment were enrolled in a randomized, open-label, parallel comparison study of 24-week add-on treatment with ciclesonide or montelukast. Patients were randomly assigned to 3 groups: ciclesonide (n = 19), montelukast (n = 22), or no add-on as controls (n = 19). At baseline and at weeks 4, 12, and 24, extended nitric oxide analysis; pulmonary function tests, including impulse oscillometry; blood eosinophil counts; and asthma control tests (ACTs) were performed. Results: A total of 18 patients in the ciclesonide group, 19 in the montelukast group, and 15 in the control group completed the study and were analyzed. With repeated-measures analysis of variance, ciclesonide produced a significant decrease in alveolar nitric oxide and a significant improvement in ACT scores over time. Montelukast produced significant decreases in alveolar nitric oxide concentrations and blood eosinophil counts over time and slightly improved ACT scores, whereas no such changes were observed in the control group. Alveolar nitric oxide concentrations with ciclesonide and reactance area at low frequencies with montelukast produced greater improvements over time compared with control. Conclusion: Ciclesonide add-on therapy and montelukast add-on therapy may act differently, but both separately can improve small airway abnormalities and provide better asthma control. Trial Registration: umin.ac.jp/ctr Identifier: UMIN000001083 (C) 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
  • Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma., Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Ito J, Niimi A, Mishima M, Ann Allergy Asthma Immunol, 110, 387 - 388,   2013年, 査読有り
  • Efficacy of Budesonide in Combination with Formoterol in Patients with Inadequately Controlled Asthma on Fluticasone in Combination with Salmeterol, Yoshihiro Kanemitsu, Hideo Kita, Akio Niimi, Yoshinori Fuseya, Kazuya Tanimura, Yuko Katayama, Tamaki Takahashi, Yukimasa Hatachi, Yumi Nishihara, Toshikatsu Sado, ALLERGOLOGY INTERNATIONAL, 61, (4) 625 - 627,   2012年12月, 査読有り
  • FDG-PETで肺結節影, 右肺門・縦隔リンパ節に集積亢進を認めたウエステルマン肺吸虫症の1例, 谷村和哉, 北英夫, 金光禎寛, 伏屋芳紀, 片山優子, 西原祐美, 千葉渉, 菅理晴, 日本呼吸器学会雑誌, 49, (4) 293 - 297,   2011年04月, 査読有り
  • Tracheo-bronchial involvement in Sweet syndrome, Kazuya Tanimura, Hideo Kita, Yoshihiro Kanemitsu, Yoshinori Fuseya, Yuko Katayama, THORAX, 65, (12) 1119 - 1120,   2010年12月, 査読有り
  • 季節性インフルエンザワクチン接種後に発症した間質性肺炎の1例, 金光 禎寛, 北, 英夫, 伏屋, 芳紀, 谷村, 和哉, 片山, 優子, 千葉, 渉 管 理晴, 日本呼吸器学会雑誌, 48, (10) 739 - 742,   2010年10月, 査読有り
  • 日本人の重症喘息患者10名に対するomalizumabの治療効果の検討, 金光 禎寛, 北 英夫, 伏屋 芳紀, 谷村 和哉, 片山 優子, 西原 祐美, アレルギー, 59, (8) 965 - 973,   2010年08月, 査読有り
  • 気管支鏡下腫瘍内エタノール注入療法により腎細胞癌気管支内転移が消失した1例, 金光 禎寛, 江村 正仁, 中村 敬哉, 酒井 茂樹, 張 孝徳, 後藤 健一, 杉尾 裕美, 気管支学, 32, (1) 36 - 40,   2010年01月, 査読有り
  • 大細胞癌の特殊型である肺原発淡明細胞癌の1剖検例, 金光 禎寛, 江村 正仁, 中村 敬哉, 酒井 茂樹, 杉尾 裕美, 張 孝徳, 肺癌, 49, (6) 847 - 851,   2009年12月, 査読有り
  • Tiotropium Attenuates Refractory Cough and Capsaicin Cough Reflex Sensitivity in Patients with Asthma., Fukumitsu K, Kanemitsu Y, Asano T, Takeda N, Ichikawa H, Yap JMG, Fukuda S, Uemura T, Takakuwa O, Ohkubo H, Maeno K, Ito Y, Oguri T, Nakamura A, Takemura M, Niimi A, J Allergy Clin Immunol Pract, 6, 1613 - 1620, 査読有り
  • Airway remodeling associated with cough hypersensitivity as a consequence of persistent cough: An experimental study., Nakaji H, Niimi A, Matsuoka H, Iwata T, Cui S, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Inoue H, Tajiri T, Nagasaki T, Kanemitsu Y, Chin K, Mishima M, Respir Investig, 54, 419 - 427, 査読有り

MISC

  • 喘息患者における将来的Omalizumab導入予測因子としてのペリオスチンの有用性の検討, 砂留 広伸, 松本 久子, 東田 有智, 堀口 高彦, 北 英夫, 桑原 和伸, 富井 啓介, 大塚 浩二郎, 藤村 政樹, 大倉 徳幸, 岩永 賢司, 保澤 総一郎, 新実 彰男, 金光 禎寛, 長崎 忠雄, 田嶋 範之, 石山 祐美, 森本 千絵, 小熊 毅, 田尻 智子, 伊藤 功朗, 小野 純也, 太田 昭一郎, 出原 賢治, 平井 豊博, 日本呼吸器学会誌, 8, (増刊) 139 - 139,   2019年03月
  • 慢性咳嗽で発症した気道異物の1例, 山本 清花, 伊藤 穣, 伊藤 圭馬, 井上 芳次, 福光 研介, 福田 悟史, 金光 禎寛, 高桑 修, 大久保 仁嗣, 竹村 昌也, 前野 健, 小栗 鉄也, 中村 敦, 新実 彰男, 気管支学, 41, (2) 213 - 213,   2019年03月
  • 再発非扁平上皮非小細胞肺癌に対するドセタキセルの治療効果とTTF-1発現, 竹内 章, 小栗 鉄也, 山下 依子, 曽根 一輝, 福田 悟史, 高桑 修, 前野 健, 福光 研介, 金光 禎寛, 大久保 仁嗣, 竹村 昌也, 伊藤 穣, 新実 彰男, 日本呼吸器学会誌, 8, (増刊) 210 - 210,   2019年03月
  • カプサイシン咳感受性は喘息の重症化を反映する, 金光 禎寛, 福光 研介, 武田 典久, 黒川 良太, 福田 悟史, 高桑 修, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 鉄也, 竹村 昌也, 新実 彰男, 日本呼吸器学会誌, 8, (増刊) 249 - 249,   2019年03月
  • 進行期非小細胞肺癌治療におけるベバシズマブ併用療法効果予測因子としてのTTF-1発現の有用性, 竹内 章, 小栗 鉄也, 山下 依子, 曽根 一輝, 福田 悟史, 高桑 修, 前野 健, 福光 研介, 金光 禎寛, 大久保 仁嗣, 竹村 昌也, 伊藤 穣, 新実 彰男, 肺癌, 58, (6) 589 - 589,   2018年10月
  • Xolair導入後の血清総IgEなどの推移, 森本千絵, 松本久子, 田尻智子, 田尻智子, 鈴川真穂, 出原裕美, 権寧博, 伊藤玲子, 橋本修, 出原賢治, 太田昭一郎, 小野純也, 大田健, 金光禎寛, 金光禎寛, 長崎忠雄, 小熊毅, 伊藤功朗, 新実彰男, 新実彰男, 平井豊博, アレルギー, 67, (4/5) 574 - 574,   2018年05月15日
  • 気管支サーモプラスティ療法により発生し,自然消退した炎症性気管支ポリープの1例, 金光 禎寛, 竹内 章, 高桑 修, 浅野 貴光, 福光 研介, 武田 典久, 黒川 良太, 竹村 昌也, 新実 彰男, アレルギー, 67, (4-5) 660 - 660,   2018年05月
  • 難治性喘息性咳嗽に対して気管支サーモプラスティが有用であった1例, 北村 有希, 金光 禎寛, 高桑 修, 浅野 貴光, 大久保 仁嗣, 伊藤 穣, 伊藤 圭馬, 井上 芳次, 福光 研介, 武田 典久, 福田 悟史, 前野 健, 小栗 鉄也, 竹村 昌也, 新実 彰男, 日本呼吸器学会誌, 7, (増刊) 326 - 326,   2018年03月
  • 内視鏡室で実施する気管支サーモプラスティ 治療中の経時的記録からみた課題の検討, 高桑 修, 金光 禎寛, 岡山 未奈美, 市川 博也, 上村 剛大, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 鉄也, 中村 敦, 新実 彰男, 気管支学, 39, (Suppl.) S277 - S277,   2017年05月
  • 気管支喘息(成人) 気管支サーモプラスティー 重症喘息患者における気管支サーモプラスティの有用性の検討, 金光 禎寛, 福光 研介, 武田 典久, 市川 博也, 浅野 貴光, 岡山 未奈実, 高桑 修, 上村 剛大, 大久保 博嗣, 前野 健, 伊藤 穣, 小栗 鉄也, 中村 敦, 竹村 昌也, 新実 彰男, アレルギー, 66, (4-5) 613 - 613,   2017年05月
  • 気管支サーモプラスティー療法が有効であった低肺機能の1例, 市川 博也, 金光 禎寛, 岡山 未奈実, 高桑 修, 上村 剛大, 武田 典久, 福光 研介, 浅野 貴光, 竹村 昌也, 新実 彰男, アレルギー, 66, (4-5) 674 - 674,   2017年05月
  • 成人喘息 病態 Omalizumab投与後も増悪が残る重症喘息例の検討, 森本 千絵, 田尻 智子, 松本 久子, 出原 裕美, 権 寧博, 伊藤 玲子, 橋本 修, 出原 賢治, 太田 昭一郎, 小野 純也, 鈴川 真穂, 大田 健, 金光 禎寛, 長崎 忠雄, 小熊 毅, 伊藤 功朗, 新実 彰男, 三嶋 理晃, アレルギー, 66, (4-5) 575 - 575,   2017年05月
  • 成人喘息の診断と検査(バイオマーカー) 血清ペリオスチン低値の喘息例における増悪因子の検討, 石山 祐美, 松本 久子, 金光 禎寛, 東田 有智, 堀口 高彦, 北 英夫, 桑原 和伸, 富井 啓介, 大塚 浩二郎, 藤村 政樹, 大倉 徳幸, 冨田 桂公, 横山 彰仁, 大西 広志, 中野 恭幸, 小熊 哲也, 保澤 総一郎, 新実 彰男, 出原 賢治, 三嶋 理晃, 森本 千絵, 砂留 広伸, 出原 裕美, 長崎 忠雄, 小熊 毅, 田尻 智子, 伊藤 功朗, 太田 昭一郎, 小野 純也, 玉利 真由美, 広田 朝光, 井上 英樹, 岩田 敏之, アレルギー, 66, (4-5) 567 - 567,   2017年05月
  • 未治療喘息患者における吸入ステロイド治療反応性に寄与する因子の検討, 福光 研介, 金光 禎寛, 岡山 未奈美, 武田 典久, 浅野 貴光, 市川 博也, 上村 剛大, 竹村 昌也, 高桑 修, 大久保 仁嗣, 伊藤 穣, 前野 健, 小栗 鉄也, 中村 敦, 新実 彰男, 日本呼吸器学会誌, 6, (増刊) 145 - 145,   2017年03月
  • EGFR遺伝子変異陰性あるいは不明進行期肺癌に対するエルロチニブ治療効果予測因子としての腫瘍マーカーの検討, 竹内 章, 小栗 鉄也, 曽根 一輝, 福田 悟史, 上村 剛大, 金光 禎寛, 大久保 仁嗣, 高桑 修, 竹村 昌也, 前野 健, 伊藤 穣, 中村 敦, 新実 彰男, 日本呼吸器学会誌, 6, (増刊) 313 - 313,   2017年03月
  • 気管支喘息の病因・病態 血清ペリオスチン低値喘息群における増悪因子, 石山 祐美, 松本 久子, 金光 禎寛, 東田 有智, 堀口 高彦, 北 英夫, 桑原 和伸, 富井 啓介, 大塚 浩二郎, 藤村 政樹, 大倉 徳幸, 富田 桂公, 横山 彰仁, 大西 広志, 中野 恭幸, 小熊 哲也, 保澤 総一郎, 新実 彰男, 出原 裕美, 長崎 忠雄, 小熊 毅, 田尻 智子, 伊藤 功朗, 出原 賢治, 三嶋 理晃, 森本 千絵, 砂留 広伸, 太田 昭一郎, 小野 純也, 玉利 真由美, 広田 朝光, 井上 英樹, 岩田 敏之, 日本呼吸器学会誌, 6, (増刊) 127 - 127,   2017年03月
  • がん疼痛に対するフェンタニル貼付剤早期導入の有用性の検討, 高桑 修, 前野 健, 金光 禎寛, 上村 剛大, 大久保 仁嗣, 竹村 昌也, 伊藤 穣, 小栗 鉄也, 中村 敦, 新実 彰男, 日本内科学会雑誌, 106, (Suppl.) 235 - 235,   2017年02月
  • 気管支サーモプラスティー療法が有効であった低肺機能の1例, 金光 禎寛, 高桑 修, 岡山 未奈実, 竹村 昌也, 上村 剛大, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 哲也, 中村 敦, 新実 彰男, 気管支学, 39, (1) 103 - 103,   2017年01月
  • 肺癌治療中に生じた食道大動脈瘻に対してステントグラフト内挿術を施行して救命した1例, 伊藤 圭馬, 上村 剛大, 小栗 鉄也, 岡山 未奈実, 金光 禎寛, 高桑 修, 大久保 仁嗣, 竹村 昌也, 前野 健, 伊藤 穣, 中村 敦, 新実 彰男, 肺癌, 56, (5) 415 - 416,   2016年10月
  • 気管支温熱療法を施行した1例, 作井 マリア, 金光 禎寛, 竹村 昌也, 岡山 未奈実, 村瀬 博紀, 上村 剛大, 高桑 修, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 哲也, 新実 彰男, 気管支学, 38, (5) 442 - 442,   2016年09月
  • 鼻副鼻腔炎合併喘息における血清ペリオスチンの測定意義, 浅野貴光, 金光禎寛, 竹村昌也, 市川博也, 福光研介, 武田典久, 土方寿聡, 太田昭一郎, 小野純也, 出原賢治, 中村善久, 鈴木元彦, 新実彰男, アレルギー, 65, (4/5) 654 - 654,   2016年05月15日
  • EBUS-TBNAにおけるHigh flow nasal cannulaの有用性 経鼻カニューラ法との比較, 市川 博也, 高桑 修, 武田 典久, 福光 研介, 金光 禎寛, 上村 剛大, 大久保 仁嗣, 竹村 昌也, 前野 健, 伊藤 穣, 小栗 鉄也, 中村 敦, 新実 彰男, 気管支学, 38, (Suppl.) S246 - S246,   2016年05月
  • IL-4RA、ADAM33多型と喘息増悪との関係, 砂留 広伸, 松本 久子, 金光 禎寛, 東田 有智, 堀口 高彦, 北 英夫, 桑原 和伸, 富井 啓介, 大塚 浩二郎, 藤村 政樹, 大倉 徳幸, 富田 桂公, 横山 彰仁, 大西 広志, 中野 恭幸, 小熊 哲也, 保澤 総一郎, 新実 彰男, 小熊 毅, 田尻 智子, 伊藤 功朗, 出原 裕美, 長崎 忠雄, 出原 賢治, 三嶋 理晃, 日本呼吸器学会誌, 5, (増刊) 291 - 291,   2016年03月
  • 口呼吸とアレルギー性鼻炎、喘息との関係 ながはま0次予防コホート事業より, 出原 裕美, 松本 久子, 長崎 忠雄, 金光 禎寛, 伊藤 功朗, 小熊 毅, 室 繁郎, 別所 和久, 田原 康玄, 松田 文彦, 中山 健夫, 新実 彰男, 陳 和夫, 三嶋 理晃, 日本呼吸器学会誌, 5, (増刊) 251 - 251,   2016年03月
  • 吸入ステロイド薬抵抗性の難治性喘息性咳嗽に対してTiotropium bromideの併用が有効であった1例, 福光 研介, 金光 禎寛, 武田 典久, 浅野 貴光, 市川 博也, 上村 剛大, 大久保 仁嗣, 高桑 修, 竹村 昌也, 伊藤 穣, 前野 健, 小栗 鉄也, 中村 敦, 新実 彰男, 日本呼吸器学会誌, 5, (増刊) 179 - 179,   2016年03月
  • 非小細胞肺癌におけるプラチナ製剤とペメトレキセド併用治療効果とFolylpoly-γ-glutamate synthase(FPGS)の遺伝子多型との関連, 福田 悟史, 小栗 鉄也, 國井 英治, 上村 剛大, 高桑 修, 前野 健, 村瀬 博紀, 金光 禎寛, 竹村 昌也, 大久保 仁嗣, 伊藤 穣, 中村 敦, 新実 彰男, 日本呼吸器学会誌, 5, (増刊) 320 - 320,   2016年03月
  • 肺癌患者の癌性胸膜炎の胸膜癒着術における滅菌調整タルクの使用経験, 長谷川 千恵, 上村 剛大, 小栗 鉄也, 國井 英治, 金光 禎寛, 高桑 修, 大久保 仁嗣, 竹村 昌也, 前野 健, 伊藤 穣, 中村 敦, 新実 彰男, 肺癌, 55, (7) 1114 - 1114,   2015年12月
  • EBUS-TBNA検査中の酸素化維持におけるネーザルハイフローの有用性, 佐々木 宏和, 高桑 修, 市川 博也, 金光 禎寛, 國井 英治, 上村 剛大, 大久保 仁嗣, 前野 健, 伊藤 穣, 小栗 鉄也, 新実 彰男, 気管支学, 37, (5) 604 - 604,   2015年09月
  • 口呼吸とアレルギー性鼻炎,喘息との関係~ながはま0次予防コホート事業より~, 出原裕美, 松本久子, 長崎忠雄, 金光禎寛, 伊藤功朗, 小熊毅, 室繁郎, 田原康玄, 別所和久, 中山建夫, 新実彰男, 新実彰男, 陳和夫, 三嶋理晃, アレルギー, 64,   2015年04月25日
  • 健常者と喘息症例におけるCTで測定した肺動脈径/大動脈径比についての検討, 小熊毅, 平井豊博, 福井基成, 出原裕美, 金光禎寛, 長崎忠雄, 佐藤晋, 松本久子, 三嶋理晃, アレルギー, 64,   2015年04月25日
  • 呼気NOと血清ペリオスチンはステロイド低感受性喘息を同定する, 長崎忠雄, 松本久子, 松本久子, 金光禎寛, 金光禎寛, 出原賢治, 東田有智, 堀口高彦, 北英寿, 富井啓介, 藤村政樹, 横山彰仁, 中野恭幸, 保澤総一郎, 伊藤功朗, 小熊毅, 田尻智子, 岩田敏之, 出原裕美, 新実彰男, 新実彰男, 三嶋理晃, 三嶋理晃, 日本呼吸器学会誌, 4,   2015年03月10日
  • 気管支喘息の病因と病態 遷延性咳嗽と咳嗽誘発・増悪因子についての疫学調査 ながはま0次予防コホート事業, 松本 久子, 出原 裕美, 新実 彰男, 長崎 忠雄, 金光 禎寛, 小熊 毅, 伊藤 功朗, 室 繁郎, 田原 康玄, 松田 文彦, 中山 健夫, 三嶋 理晃, 日本呼吸器学会誌, 4, (増刊) 134 - 134,   2015年03月
  • イヌ、ネコへの乳児期曝露が壮年期以降のアレルギー疾患に与える影響 ながまはコホート事業から, 出原 裕美, 松本 久子, 長崎 忠雄, 金光 禎寛, 小熊 毅, 伊藤 功朗, 室 繁郎, 新実 彰男, 田原 康玄, 松田 文彦, 中山 健夫, 三嶋 理晃, 日本呼吸器学会誌, 4, (増刊) 275 - 275,   2015年03月
  • 重症喘息における血清free IgE値とomalizumab反応性との関連, 田尻智子, 松本久子, 権寧博, 伊藤玲子, 出原裕美, 金光禎寛, 長崎忠雄, 岩田敏之, 井上英樹, 小熊毅, 伊藤功朗, 新実彰男, 三嶋理晃, アレルギー, 63,   2014年04月05日
  • 未治療咳喘息に対するブデソニド/ホルモテロール配合剤とブデソニド単剤治療の比較検討, 岩田敏之, 新実彰男, 松本久子, 伊藤功朗, 小熊毅, 竹村昌也, 福井基成, 大塚浩二郎, 富井啓介, 竹田知史, 上田哲也, 長谷川吉則, 松岡弘典, 鈴木雄二郎, 井上英樹, 田尻智子, 長崎忠雄, 金光禎寛, 三嶋理晃, アレルギー, 63,   2014年04月05日
  • 治療下喘息例における黄色ブドウ球菌スーパー抗原への感作と喘息病態との関係, 金光禎寛, 松本久子, 東田有智, 堀口高彦, 北英夫, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 冨田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 長崎忠雄, 出原裕美, 伊藤功朗, 小熊毅, 井上英樹, 田尻智子, 岩田敏之, 新実彰男, 三嶋理晃, アレルギー, 63,   2014年04月05日
  • 咳嗽の評価と管理 本邦における遷延性咳嗽についての疫学調査 ながはま0次予防コホート研究より, 出原 裕美, 松本 久子, 長崎 忠雄, 金光 禎寛, 田尻 智子, 小熊 毅, 伊藤 功朗, 室 繁郎, 新実 彰男, 田原 康玄, 中山 健夫, 小杉 眞司, 関根 章博, 松田 文彦, 三嶋 理晃, アレルギー, 63, (3-4) 504 - 504,   2014年04月
  • 健診者における血清IgE値に対する喫煙歴と年齢の影響 ながはま0次予防コホート事業, 長崎 忠雄, 松本 久子, 出原 裕美, 金光 禎寛, 田尻 智子, 小熊 毅, 伊藤 功朗, 室 繁郎, 田原 康玄, 関根 章博, 小杉 眞司, 松田 文彦, 中山 健夫, 三嶋 理晃, アレルギー, 63, (3-4) 600 - 600,   2014年04月
  • CTを用いた閉塞性肺疾患における気管支内腔の不整度に関する検討, 小熊毅, 平井豊博, 松本久子, 伊藤功朗, 田尻智子, 長崎忠雄, 金光禎寛, 出原裕美, 室繁郎, 三嶋理晃, 日本呼吸器学会誌, 3,   2014年03月10日
  • 喘息患者における過去喫煙の末梢気道病変への影響, 長崎忠雄, 松本久子, 伊藤功朗, 小熊毅, 井上英樹, 岩田敏之, 田尻智子, 金光禎寛, 出原裕美, 新実彰男, 三嶋理晃, 日本呼吸器学会誌, 3,   2014年03月10日
  • 吸入ステロイド治療下喘息患者におけるGLCCI1遺伝子多型と呼吸機能低下との関連についての検討, 出原裕美, 松本久子, 金光禎寛, 出原賢治, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 富田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 長崎忠雄, 伊藤功朗, 小熊毅, 岩田敏之, 田尻智子, 新美彰男, 三嶋理晃, 日本呼吸器学会誌, 3,   2014年03月10日
  • オステオポンチンとペリオスチンは喘息患者の長期的な呼吸機能低下に寄与する, 金光禎寛, 伊藤功朗, 新実彰男, 松本久子, 岩田敏之, 出原賢治, 太田昭一郎, 小野純也, 小熊毅, 田尻智子, 長崎忠雄, 出原裕美, 三嶋理晃, 日本呼吸器学会誌, 3, (増刊) 140 - 140,   2014年03月10日
  • MS3-1 本邦における遷延性咳漱についての疫学調査 : ながはま0次予防コホート研究より(MS3 咳漱の評価と管理,ミニシンポジウム,第26回日本アレルギー学会春季臨床大会), 出原 裕美, 田原 康玄, 中山 健夫, 小杉 眞司, 関根 章博, 松田 文彦, 三嶋 理晃, 松本 久子, 長崎 忠雄, 金光 禎寛, 田尻 智子, 小熊 毅, 伊藤 功朗, 室 繁郎, 新実 彰男, アレルギー, 63,   2014年
  • 喘息患者における過去喫煙の末梢気道炎症への影響, 長崎忠雄, 松本久子, 伊藤功朗, 小熊毅, 井上英樹, 岩田敏之, 田尻智子, 金光禎寛, 出原裕美, 新実彰男, 三嶋理晃, アレルギー, 62,   2013年10月25日
  • 吸入ステロイド治療下喘息患者におけるGLCCI1遺伝子多型と呼吸機能低下との関連についての検討, 出原裕美, 松本久子, 金光禎寛, 出原賢治, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 冨田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 長崎忠雄, 伊藤功朗, 小熊毅, 田尻智子, 新実彰男, 三嶋理晃, 小野純也, 岩田敏之, 玉利真由美, アレルギー, 62,   2013年10月25日
  • osteopontinとperiostinは喘息患者の長期的な呼吸機能低下に寄与する, 金光禎寛, 伊藤功朗, 新実彰男, 松本久子, 岩田敏之, 出原賢治, 太田昭一郎, 小野純也, 小熊毅, 田尻智子, 長崎忠雄, 出原裕美, 三嶋理晃, アレルギー, 62, (9/10) 1390 - 1390,   2013年10月25日
  • Hot Topics in気管支喘息 好酸球性炎症と気道リモデリングにおけるペリオスチンの役割と意義, 金光 禎寛, 松本 久子, 日本小児アレルギー学会誌, 27, (3) 331 - 331,   2013年08月
  • 喘息性咳嗽における胃食道逆流症状と咳嗽誘発因子との関係, 長崎忠雄, 松本久子, 金光禎寛, 伊藤功朗, 小熊毅, 岩田敏之, 田尻智子, 出原裕美, 新実彰男, 三嶋理晃, アレルギー, 62,   2013年04月10日
  • 吸入ステロイド(ICS)治療下喘息におけるシクレソニドとモンテルカストの追加効果の検討, 中治仁志, 松本久子, GUERGANA Petrova, 岩田敏之, 新実彰男, 伊藤功朗, 小熊毅, 井上英樹, 田尻智子, 長崎忠雄, 金光禎寛, 三嶋理晃, 日本呼吸器学会誌, 2,   2013年03月10日
  • ペリオスチンは吸入ステロイド治療下喘息患者の呼吸機能低下の進行に関与する, 金光禎寛, 松本久子, 出原賢治, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 冨田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 長崎忠雄, 伊藤功朗, 小熊毅, 井上英樹, 田尻智子, 岩田敏之, 出原裕美, 大田昭一郎, 玉利真由美, 広田智光, 小野純弥, 横山徹爾, 新実彰男, 三嶋理晃, 日本呼吸器学会誌, 2,   2013年03月10日
  • 典型的喘息及び咳喘息における誘発喀痰中MUC5ACの臨床的意義, 田尻智子, 新実彰男, 松本久子, 陣内牧子, 伊藤功朗, 小熊毅, 岩田敏之, 長崎忠雄, 金光禎寛, 出原裕美, 三嶋理晃, 日本呼吸器学会誌, 2,   2013年03月10日
  • クラスター解析による喘息フェノタイプ分類と呼吸機能の経年変化との関係, 長崎忠雄, 松本久子, 金光禎寛, 出原賢治, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 冨田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 伊藤功朗, 小熊毅, 田尻智子, 岩田敏之, 出原裕美, 太田昭一郎, 小野純也, 新実彰男, 三嶋理晃, 日本呼吸器学会誌, 2, (増刊) 283 - 283,   2013年03月10日
  • 線毛運動異常マウスは後鼻漏により自発的に咳をする, 岩田敏之, 伊藤功朗, 新実彰男, 池上浩司, 丸毛聡, 田辺直也, 中治仁志, 松本久子, 小熊毅, 井上英樹, 田尻智子, 長崎忠雄, 金光禎寛, 亀井淳三, 瀬藤光利, 三嶋理晃, アレルギー, 61,   2012年10月25日
  • 典型的喘息および咳喘息における誘発喀痰中MUC5ACの臨床的意義, 田尻智子, 新実彰男, 松本久子, 陣内牧子, 伊藤功朗, 小熊毅, 井上英樹, 岩田敏之, 長崎忠雄, 金光禎寛, PETROVA Guergana, 崔石磊, 出原裕美, 三嶋理晃, アレルギー, 61,   2012年10月25日
  • クラスター解析による喘息フェノタイプ分類と呼吸機能の経年変化との関係, 長崎忠雄, 松本久子, 金光禎寛, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 富田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 新実彰男, 伊藤功朗, 小熊毅, 田尻智子, 岩田敏之, 出原裕美, 三嶋理晃, アレルギー, 61,   2012年10月25日
  • 吸入ステロイド治療下喘息患者における呼吸機能低下に関与する因子の検討, 金光禎寛, 松本久子, 出原賢治, 東田有智, 北英夫, 堀口高彦, 桑原和伸, 富井啓介, 大塚浩二郎, 藤村政樹, 大倉徳幸, 富田桂公, 横山彰仁, 大西広志, 中野恭幸, 小熊哲也, 保澤総一郎, 長崎忠雄, 伊藤功朗, 小熊毅, 田尻智子, 岩田敏之, 新実彰男, 三嶋理晃, アレルギー, 61,   2012年10月25日
  • 吸入ステロイド(ICS)治療下喘息例におけるシクレソニドとモンテルカストの追加効果の検討, 中治仁志, GUERGANA Petrova, 松本久子, 岩田敏之, 新実彰男, 伊藤功朗, 小熊毅, 井上英樹, 田尻智子, 長崎忠雄, 金光禎寛, 三嶋理晃, アレルギー, 61,   2012年10月25日
  • IgG4陽性細胞浸潤を伴った細気管支炎の一例, 伊藤功朗, 新実彰男, 金光禎寛, 松本久子, 三嶋理晃, 気管支学, 34, (Suppl.) S196 - S196,   2012年05月20日
  • ST2遺伝子多型の気管支喘息表現型に与える影響, 井上英樹, 伊藤功朗, 新実彰男, 松本久子, 小熊毅, 田尻智子, 岩田敏之, 長崎忠雄, 金光禎寛, 広田朝光, 玉利真由美, 三嶋理晃, アレルギー, 61,   2012年04月10日
  • 好酸球性副鼻腔炎及び中耳炎に対するomalizumabの有効性に関する検討, 田尻智子, 松本久子, 新実彰男, 森田恭平, 池田浩己, 伊藤功朗, 小熊毅, 井上英樹, 岩田敏之, 長崎忠雄, 金光禎寛, 三嶋理晃, アレルギー, 61,   2012年04月10日
  • TTLL 1 KOマウスは後鼻漏により自発的に咳をする, 岩田敏之, 伊藤功朗, 新実彰男, 池上浩司, 丸毛聡, 田辺直也, 中治仁志, 松本久子, 小熊毅, 井上英樹, 田尻智子, 長崎忠雄, 金光禎寛, 亀井淳三, 瀬藤光利, 三嶋理晃, 日本呼吸器学会誌, 1,   2012年03月10日
  • 咳喘息におけるレスター咳質問票(LCQ)の臨床的意義, 金光禎寛, 新実彰男, 松本久子, 伊藤功朗, 小熊毅, 井上英樹, 田尻智子, 岩田敏之, 長崎忠雄, 三嶋理晃, 日本呼吸器学会誌, 1,   2012年03月10日
  • 安定期喘息患者における誘発喀痰中好酸球比率とCTで評価した中枢気道壁肥厚との関連, 井上英樹, 伊藤功朗, 新実彰男, 松本久子, 小熊毅, 田尻智子, 岩田敏之, 長崎忠雄, 金光禎寛, 三嶋理晃, 日本呼吸器学会誌, 1,   2012年03月10日
  • 重症難治性喘息に対するOmalibumabの有効性に関する包括的検討, 田尻智子, 新実彰男, 松本久子, 伊藤功朗, 小熊毅, 金光禎寛, 長崎忠雄, 岩田敏之, 井上英樹, 中治仁志, 大塚浩二郎, 竹田知史, 三嶋理晃, 日本呼吸器学会誌, 1,   2012年03月10日
  • MDCTで評価した安定期喘息患者における中枢気道の呼気時虚脱性と呼気モザイクパターンの関連, 小熊毅, 新実彰男, 松本久子, 伊藤功朗, 井上英樹, 岩田敏之, 田尻智子, 長崎忠雄, 金光禎寛, 平井豊博, 三嶋理晃, 日本呼吸器学会誌, 1,   2012年03月10日

書籍等出版物

  • 喘息 診断と治療のABC, 金光 禎寛, 分担執筆, 気管支サーモプラスティ, 最新医学社,   2018年06月

受賞

  •   2019年11月, 令和1年度名古屋市立大学学長表彰
  •   2019年04月, 2018年度名古屋市立大学医学部BSLベストティーチャー賞
  •   2019年04月, 日本内科学会ことはじめ2019名古屋 指導教官賞
  •   2019年04月, 平成31年度日本呼吸器学会・学会奨励賞
  •   2015年10月, 日本咳嗽研究会, 第17回日本咳嗽研究会 優秀演題賞
  •   2014年09月, European Respiratory Society, The ERS Abstract Grant for JRS Delegate 2014
  •   2014年09月, 京都大学大学院医学部, 平成25年度京都大学医学部若手研究者優秀論文賞KMYIA
  •   2013年04月, 日本呼吸器学会, 第53回日本呼吸器学会Best Presentation Award
  •   2012年11月, 日本アレルギー学会, 第9回日本アレルギー学会学術大賞
  •   2010年05月, 日本アレルギー学会, 第22回日本アレルギー学会春季臨床大会ポスター大賞


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.